According to Fortune Business Insights, the global pulmonary drug delivery market size was valued at USD 58.63 billion in 2025. The market is projected to grow from USD 61.36 billion in 2026 to USD 88.38 billion by 2034, exhibiting a CAGR of 4.67% during the forecast period (2026–2034). This growth is driven by increasing respiratory disease prevalence, rising demand for inhalation therapies, and expanding adoption of pulmonary drug delivery devices across hospitals, clinics, and homecare settings.
Pulmonary drug delivery involves the administration of therapeutic medications directly into the respiratory tract through specialized devices such as inhalers and nebulizers. These systems enable targeted drug delivery to the lungs, improving treatment efficiency while reducing systemic drug exposure.
The market includes a broad range of instruments, accessories, inhalers, and nebulizers designed for different respiratory conditions and patient populations. Pulmonary drug delivery devices are widely used across hospitals, ambulatory surgical centers, clinics, and homecare settings, reflecting their importance in both acute and long-term respiratory care.
For detailed market insights: https://www.fortunebusinessinsights.com/pulmonary-drug-delivery-market-111880
The pulmonary drug delivery market is being influenced by several important healthcare and technology trends.
One of the major trends is the increasing adoption of advanced inhalation therapies for chronic respiratory disease management. Healthcare providers are increasingly relying on inhalers and nebulizers to deliver targeted pulmonary treatments.
Another significant trend is the growing use of nebulizer technologies, including jet nebulizers, ultrasonic nebulizers, and mesh nebulizers. These technologies provide flexible drug delivery options for patients with different respiratory conditions and treatment requirements.
The market is also witnessing rising demand for homecare respiratory treatment solutions. Patients and healthcare providers are increasingly adopting pulmonary drug delivery devices that enable effective treatment outside traditional hospital environments.
In addition, ongoing innovation in drug delivery instruments and accessories is improving treatment convenience, device performance, and patient adherence.
Several factors are contributing to the growth of the pulmonary drug delivery market.
The increasing prevalence of respiratory diseases is a primary market driver. Rising cases of COPD, asthma, cystic fibrosis, and other pulmonary disorders are generating strong demand for effective inhalation therapies.
The growing need for targeted pulmonary drug delivery is also supporting market expansion. Direct delivery of medications to the lungs improves therapeutic effectiveness and supports better respiratory disease management.
Expanding homecare treatment adoption is further accelerating market growth. Patients increasingly prefer convenient treatment options that can be administered outside hospitals and clinical facilities.
Additionally, continuous advancements in inhaler and nebulizer technologies are improving treatment efficiency, patient comfort, and clinical outcomes.
The pulmonary drug delivery market is segmented by type, product, application, end user, and region.